Protoacoustic Imaging to See Radiation Delivery in Proton Therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates a new imaging approach called radioacoustic imaging (RAI) that uses external ultrasound sensors to detect sound signals produced by proton therapy. The goal is to create real-time visualizations of dose deposition without extra radiation exposure or procedures. Participants receive standard X-ray alignment and then have an ultrasound matrix placed over the lower abdomen to capture signals during beam delivery, aiming to verify dose accuracy and track motion. Data will assess whether RAI can safely and effectively visualize where protons deposit their energy in moving targets like the liver and prostate. No additional interventions beyond the imaging modality are required if feasible within routine care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients at least \>18years old
* Patients referred to OUHSC SCC for SOC PT
* Patients receiving treatment for indications where RAI data collection is feasible (e.g., liver and prostate)
* Willingness and ability to provide a documented informed consent

Exclusion Criteria:

* Patients with contraindications for ultrasound coupling (e.g., extensive open wounds or skin conditions at transducer placement sites).
* Patients whose treatment plan or setup prevents the practical application of the RAI system without interfering with standard clinical care
* Patients with implanted electronic devices (e.g., pacemakers) in the treatment region if there is any concern of device interference, even though the RAI system is passive.

Where it's running

• OU Health Stephenson Cancer Center
  Oklahoma City, Oklahoma, United States Recruiting

Study contacts

• Principal investigator: Yong Chen, PhD — University of Oklahoma - Stephenson Cancer Center
• Study coordinator: Lead Onco Nurse
• Email: SCC-IIT-Office@ouhsc.edu
• Phone: (405) 271-3016

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SL-28 for Advanced Solid Tumours

  A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.

  Recruiting Phase 1/2 Second Life Therapeutics · Sydney, New South Wales and 2 other locations · NCT07341737

• Collecting blood and leftover tumor tissue to test molecular residual disease (MRD) detection

  This project will test whether blood and leftover tumor tissue from adults with certain solid tumors can be used with Natera's MRD blood tests to find tiny amounts of cancer (ctDNA) after treatment.

  Recruiting Natera, Inc. · Austin, Texas · NCT07318051

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

• ImmunoPET imaging for solid tumors targeting Trop2

  This study is testing a new imaging method to see if it can help diagnose solid tumors like bladder and prostate cancer better than current methods.

  Recruiting Phase 2/3 RenJi Hospital · Shanghai · NCT06851663

• Using brodalumab to treat immune-related side effects from cancer therapy

  This study is testing if brodalumab can help cancer patients who are having immune-related side effects from their immunotherapy treatment feel better.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06673329

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.